What is IN8bio?
Founded in 2016 and headquartered in New York, IN8bio is dedicated to pioneering next-generation cellular therapies for cancer treatment. The company's innovative pipeline includes allogeneic, autologous, and genetically modified gamma-delta T cell therapies, positioning it at the forefront of immuno-oncology research and development. The substantial late-stage funding suggests a strong market validation for its therapeutic approach.
How much funding has IN8bio raised?
IN8bio has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in IN8bio
PPP
Public-Private Partnership
What's next for IN8bio?
With a significant late-stage funding context, IN8bio is poised for accelerated growth and the potential scaling of its therapeutic programs. This strategic investment is likely to fuel further clinical development, expand manufacturing capabilities, and potentially support regulatory submissions. The company's focus on gamma-delta T cell therapies indicates a strategic move towards novel treatment modalities that could address unmet needs in oncology.
See full IN8bio company page